Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZNNASDAQ:KTTANASDAQ:PULMNASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.04+4.5%$0.98$0.64▼$15.06$6.86M-0.01567,038 shs145,011 shsKTTAPasithea Therapeutics$1.19-4.0%$1.51$0.92▼$9.25$3.22M0.75531,305 shs25,154 shsPULMPulmatrix$6.06-1.3%$7.59$1.72▼$10.40$22.12M1.55131,899 shs18,945 shsSBFMSunshine Biopharma$2.25+8.2%$2.38$1.66▼$248.00$2.75M1.35553,844 shs67.83 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro+4.51%+4.00%+37.64%-13.33%-88.56%KTTAPasithea Therapeutics-4.03%-13.77%+8.18%-59.39%-83.70%PULMPulmatrix-1.30%-9.96%-22.21%-20.78%+254.39%SBFMSunshine Biopharma+8.17%+5.63%-2.60%-28.12%-72.53%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALZNAlzamend Neuro3.6071 of 5 stars3.55.00.00.03.14.20.0KTTAPasithea Therapeutics0.629 of 5 stars0.05.00.00.00.00.80.6PULMPulmatrix0.0605 of 5 stars0.03.00.00.00.00.00.0SBFMSunshine Biopharma2.5463 of 5 stars3.53.00.00.03.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 3.00Buy$20.001,823.08% UpsideKTTAPasithea Therapeutics 0.00N/AN/AN/APULMPulmatrix 0.00N/AN/AN/ASBFMSunshine Biopharma 3.00Buy$15.00566.67% UpsideCurrent Analyst Ratings BreakdownLatest SBFM, KTTA, PULM, and ALZN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025ALZNAlzamend NeuroAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $20.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A($3.52) per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$22.46 per shareN/APULMPulmatrix$7.81M2.83N/AN/A$4.93 per share1.23SBFMSunshine Biopharma$32.96M0.08N/AN/A$1,651.69 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$9.95MN/A0.00N/AN/AN/AN/A-289.14%N/AKTTAPasithea Therapeutics-$15.96M-$12.69N/A∞N/AN/A-81.57%-74.31%5/12/2025 (Estimated)PULMPulmatrix-$14.12M-$2.61N/A∞N/A-96.51%-45.97%-30.72%5/8/2025 (Estimated)SBFMSunshine Biopharma-$4.51M-$150.88N/A∞N/A-12.82%-17.89%-14.25%N/ALatest SBFM, KTTA, PULM, and ALZN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/24/2025Q4 2024KTTAPasithea TherapeuticsN/A-$2.41N/A-$2.41N/AN/A3/21/2025Q4 2024PULMPulmatrixN/A-$0.54N/A-$0.54N/AN/A3/10/2025Q3 2025ALZNAlzamend Neuro-$0.29-$0.19+$0.10-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A3.803.80KTTAPasithea TherapeuticsN/A14.8214.82PULMPulmatrixN/A19.4019.40SBFMSunshine BiopharmaN/A5.743.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%KTTAPasithea Therapeutics23.92%PULMPulmatrix11.84%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro30.21%KTTAPasithea Therapeutics16.30%PULMPulmatrix0.62%SBFMSunshine Biopharma0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro46.60 million4.86 millionNo DataKTTAPasithea Therapeutics32.71 million1.06 millionNot OptionablePULMPulmatrix203.65 million3.63 millionNot OptionableSBFMSunshine Biopharma31.22 million1.22 millionNot OptionableSBFM, KTTA, PULM, and ALZN HeadlinesRecent News About These CompaniesThis Pharma Stock Is Gaining Major Steam Ahead Of Opening BellApril 2 at 2:13 PM | msn.comSunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq RulesApril 2 at 1:20 PM | accessnewswire.comSunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer DrugApril 2 at 11:35 AM | benzinga.comSunshine Biopharma Announces Positive Results of mRNA Therapy for CancerApril 2 at 9:12 AM | finance.yahoo.comSunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last YearApril 1 at 5:09 PM | accessnewswire.comShort Interest in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Rises By 78.1%March 31 at 3:41 AM | americanbankingnews.comSunshine Biopharma signs agreement for rights to market two generic antibioticsMarch 24, 2025 | msn.comSunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in CanadaMarch 24, 2025 | accessnewswire.comSunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | finanznachrichten.deSunshine Biopharma’s Nora Pharma acquires gastrointestinal drug rightsMarch 10, 2025 | markets.businessinsider.comSunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | accessnewswire.comSunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODTJanuary 21, 2025 | accessnewswire.comSunshine Biopharma Announces the Appointment of New Chief Commercial OfficerJanuary 15, 2025 | accesswire.comSunshine Biopharma Announces Novel Inhibitor for Sars CoronavirusDecember 9, 2024 | accesswire.comSunshine Biopharma introduces new drug, Ursodiol for management of cholestatic liver diseases, including PBCNovember 25, 2024 | pharmabiz.comSunshine Biopharma Launches a New Generic Prescription DrugNovember 22, 2024 | accesswire.comSunshine Biopharma reports Q3 revenue $8.4M vs. $5.96M last yearNovember 7, 2024 | markets.businessinsider.comSunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%November 6, 2024 | accesswire.comSunshine Girls: Photos and Gallery | Calgary SunNovember 2, 2024 | calgarysun.comSunshine Biopharma (NASDAQ:SBFM) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBFM, KTTA, PULM, and ALZN Company DescriptionsAlzamend Neuro NASDAQ:ALZN$1.04 +0.04 (+4.51%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.98 -0.06 (-5.77%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Pasithea Therapeutics NASDAQ:KTTA$1.19 -0.05 (-4.03%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.20 +0.01 (+0.84%) As of 05:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Pulmatrix NASDAQ:PULM$6.06 -0.08 (-1.30%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$6.06 0.00 (-0.07%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.Sunshine Biopharma NASDAQ:SBFM$2.25 +0.17 (+8.17%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.78 -0.47 (-20.89%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
